AP
APLMW
Apollomics Inc.
$0.0139
0.00%
$34.7K
No data for this timeframe.
Vol
Market Cap$34.7K
Cap SizeNano Cap
SEC Reports4
Recent Activity
Jun 3, 2026
SEC
Apollomics Inc.'s F-3 shelf registration (File No. 333-294154) was declared effective by the SEC on June 2, 2026. This a
EFFECT — Impact 5/10
Apr 27, 2026
SEC
Apollomics reported a $8.5 million revenue gain from a licensing deal with LaunXP, a 64% reduction in operating expenses
6-K — Impact 6/10
Apr 27, 2026
earnings
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
<p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/
Apr 24, 2026
SEC
Apollomics reported a net loss of $10.9 million for 2025, with only $3.3 million in cash as of year-end, insufficient to
20-F — Impact 7/10
Latest Reports
BEARISH
EFFECT
5/10
Apollomics Inc.'s F-3 shelf registration (File No. 333-294154) was declared effective by the SEC on June 2, 2026. This a
Jun 3, 2026
MIXED
6-K
6/10
Apollomics reported a $8.5 million revenue gain from a licensing deal with LaunXP, a 64% reduction in operating expenses
Apr 27, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 2 mixed, 0 neutral. Avg impact: 6.0/10.
BEARISH
EFFECT
5/10
Apollomics Inc.'s F-3 shelf registration (File No. 333-294154) was declared effective by the SEC on
Jun 3, 2026
MIXED
6-K
6/10
Apollomics reported a $8.5 million revenue gain from a licensing deal with LaunXP, a 64% reduction i
Apr 27, 2026
BEARISH
20-F
7/10
Apollomics reported a net loss of $10.9 million for 2025, with only $3.3 million in cash as of year-
Apr 24, 2026
MIXED
6-K
6/10
Apollomics Inc. issued a $2 million unsecured, zero-interest convertible promissory note to its CEO,
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 27, 2026
earnings
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
<p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZO